FIP Treatment

This discussion is presented by key FIP researchers from Australia, the UK, and the US. This webinar will update clinicians regarding the recent, significant advancements in FIP treatment and how legal access to GS-441524 in the US unfolded.

1. This webinar will introduce the key antivirals of interest in FIP treatment.
2. Participants will gain a concise and chronological review of the recent evidence-based literature in FIP treatment from around the globe
3. Participants will gain an understanding of why compounded access to GS-441524 is legal in Australia, the UK/Japan and now the US and how the quality assurance of compounded formulations differs from unlicensed formulations

Dr Samantha Taylor, BVetMed(Hons) CertSAM DipECVIM-CA MANZCVS FRCVS, is an RCVS Recognised Specialist in FelineMedicine, European Specialist in Veterinary Internal Medicine and a Fellow of the RCVS. She has worked in both University and private referral practice and currently works at Lumbry Park Veterinary Specialists as a medicine clinician and for International Cat Care as the Veterinary Specialist Lead. She is an Honorary Lecturer in internal medicine at the University of Surrey and set up the FIP advice email service with other specialists which has answered over 2000 emails about the novel treatments from around the world. She recently published a report on over 300 cats treated for FIP and continues to be involved in FIP research. 

Dr. Sally Coggins, BVSc (Hons I) MANZCVS (Feline Medicine), PhD (Science) Sydney School of Veterinary Science, The University of Sydney, Australia, graduated from The University of Sydney, Australia in 2007 and has been a feline-only clinician since 2010. She attained memberships in feline medicine with the ANZCVS in 2012, was a director at The Cat Clinic Melbourne, an examiner with the ANZCVS, and tutors for the Centre for Veterinary Education. Since 2020, Sally has been completing a PhD investigating antiviral therapies for FIP, where she conducted a national prospective study utilizing remdesivir and GS-441524; characterized the in vitro and in vivo pharmacokinetics of remdesivir in cats with FIP; co-authored a retrospective collaborative study assessing treatment outcomes of 307 cats treated with remdesivir and GS-441524 and has ongoing research collaboration with the US, UK, Germany and New Zealand. Sally also continues to practice clinically one day a week at Evervet in Melbourne, Australia. 

Dr. Samantha Evans DVM, PhD, DACVP, is a native of Boulder, Colorado and attended Colorado State University for her BS in chemistry, followed by a combined DVM/PhD program at the University of California Davis, where her PhD dissertation focused on feline immunodeficiency virus (FIV) latency. Next, Dr. Evans completed a medicine and surgery internship at Michigan State University and then circled back to CSU for a residency in clinical pathology. She was faculty at the Ohio State University for four years but is now back home in Colorado as an assistant professor of clinical pathology at CSU’s College of Veterinary Medicine and Biomedical Sciences.  Dr. Evans lives in Fort Collins with 1 dog, 2 cats, 3 babies, and her husband David, and studies feline infectious peritonitis (FIP) from both diagnostic and therapeutic perspectives.

3:26 Stokes & Bova introduction
4:25 GS-441524 drug details & how to order
6:54 Bova Group Introduction
10:16 Speaker introductions
12:42 Intro to nucleoside & nucleotide analogues in cats
21:43 Australia’s legal access to Bova in 2020
22:49 FIP treatment outcomes & survival rates in Australia
28:18 How the UK gained legal access with BOVA
31:05 Antiviral use in the UK
31:51 UK-based studies of treatment response
33:40 Response rates in the UK
37:31 Compliance for caregivers
39:36 Recap of studies
41:45 Use of unlicensed antivirals for FIP in the US
55:42 Status of compounded GS-441524 in the US
1:00:07 Q&A